Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; purified talc; iron oxide yellow; silicon dioxide; polyvinyl alcohol; macrogol 3350; sodium stearylfumarate; titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; polyvinyl alcohol; microcrystalline cellulose; silicon dioxide; sodium stearylfumarate; titanium dioxide; macrogol 3350; purified talc - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: ethanol; benzyl alcohol; benzyl benzoate; castor oil - fulvestrant-aft is indicated for the treatment of postmenopausal women with:,? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.,? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

Nigeria - Kiingereza - NAFDAC (National Agency for Food and Drugs Administration and Control)

recombinant human epidermal growth factor

Nigeria - Kiingereza - NAFDAC (National Agency for Food and Drugs Administration and Control)

recombinant human epidermal growth factor 60ug

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unam pharmaceutical (m) sdn bhd - paracetamol -

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unam pharmaceutical (m) sdn bhd - paracetamol; caffeine -

Marekani - Kiingereza - NLM (National Library of Medicine)

jubilant hollisterstier llc - bos taurus hair (unii: toq97z8644) (bos taurus hair - unii:toq97z8644), bos taurus dander (unii: c8vys726o8) (bos taurus dander - unii:c8vys726o8) - equus caballus hair 0.01 g in 1 ml - non-standardized allergenic extracts are indicated for: - skin test diagnosis of individuals with a clinical history of allergy to the specific corresponding allergens. non-standardized allergenic extracts are indicated for: - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for allergen specific ige antibodies for the specific corresponding allergens. non-standardized allergenic extracts are contraindicated in individuals with the following conditions: - severe, unstable or uncontrolled asthma. - history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment. - medical conditions that reduce the ability to survive anaphylaxis. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti

Marekani - Kiingereza - NLM (National Library of Medicine)

jubilant hollisterstier llc - yeast (unii: 3ny3sm6b8u) (yeast - unii:3ny3sm6b8u) - equus caballus hair 0.01 g in 1 ml - non-standardized allergenic extracts are indicated for: - skin test diagnosis of individuals with a clinical history of allergy to the specific corresponding allergens. non-standardized allergenic extracts are indicated for: - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for allergen specific ige antibodies for the specific corresponding allergens. non-standardized allergenic extracts are contraindicated in individuals with the following conditions: - severe, unstable or uncontrolled asthma. - history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment. - medical conditions that reduce the ability to survive anaphylaxis. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti

Saudi - Kiingereza - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

chemifarma s.p.a., italy - tiamulin - oral solution - 100 mg/ml